Clinical Trials Logo

Breast Cancer clinical trials

View clinical trials related to Breast Cancer.

Filter by:

NCT ID: NCT05359783 Active, not recruiting - Breast Cancer Clinical Trials

Sentinel Node Localization and Staging With Low Dose Superparamagnetic Iron Oxide

MAGSNOW
Start date: November 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Sentinel lymph node (SLN) status is pivotal for treatment decisions in breast cancer patients. The dual technique with Technetium99m (Tc99) and blue dye (BD) is yet the current routine for SLN detection. However, the same reliability has been presented by superparamagnetic iron oxide nanoparticles (SPIO). The aim of this study was to determine if SLN detection using ultra-low dose SPIO is feasible.

NCT ID: NCT05359120 Recruiting - Breast Cancer Clinical Trials

Pyrotinib Combined With Capecitabine in HER-2 Positive Advanced Breast Cancer and Brain Metastases (Post-PERMEATE)

Start date: May 30, 2022
Phase:
Study type: Observational

This study aims to describe the different treatment time, treatment mode and clinical outcomes of pyrotinib maleate tablets combined with capecitabine in the treatment of patients with HER-2 positive advanced breast cancer with brain metastases.

NCT ID: NCT05358093 Not yet recruiting - Clinical trials for Breast Cancer Female

Cardiac Toxicity of Hypo Fractionated Radiotherapy in Left Breast Cancer

Start date: April 27, 2022
Phase:
Study type: Observational

Worldwide, Breast cancer is the most common cancer in women,where 1.7 million new cases diagnosed in 2012 . In 2020 number doubled as 2.3 million women diagnosed with breast cancer. According to ACS 1 in 8 women in United states will develop breast cancer in her life . Similarly again, In Egypt breast cancer is the most common malignancy in women about 22,700 new cases recorded in 2020. Accounting for 38.8% of cancers in this population and forecasted to be approximately 46,000 in 2050 . Post-operative radiotherapy is fundamental part of treatment after either conservative surgery or mastectomy . Conventionally fractionated radiation therapy (CFRT) ,Delivering 45-50 GY in 1.8-2 GY daily fractions for 5 days per week over 5-7 weeks was the standard schedule to eradicate sub clinical disease ,sparing normal tissues .After the publication of long term results of randomized controlled trials (RCTs) comparing safety and effectiveness of hypo fractionated RT (HFRT)delivered in3 weeks ,vs. CFRT in node negative BC has been implemented . in 2008 numerous international guidelines recommended HFRT as the new standard being Cost effectiveness ,limited resources ,excessively long RT waiting lists ,Another important argument for HFRT utilization ,even assuming alpha/beta of 1.5GY ,is biologically milder or isoeffective for healthy tissues compered to CFRT . Cardiac toxicity is potentially long or short term complication of various anticancer therapies systemic therapy as anthracyclines or biological agent implicated in causing irreversible cardiac dysfunction. Radiotherapy also have cardio toxic effect through different mechanisms

NCT ID: NCT05357417 Recruiting - Breast Cancer Clinical Trials

Utidelone Plus Bevacizumab for Advanced Breast Cancer With Brain Metastases

Start date: April 29, 2022
Phase: Phase 2
Study type: Interventional

This study aims to investigate the efficacy and safety of utidelone in combination with bevacizumab in the treatment of advanced breast cancer with brain metastases, and thus provides a new systemic treatment strategy for those patients.

NCT ID: NCT05354882 Recruiting - Breast Cancer Clinical Trials

Interventional Study on DEterminants and Factors of Physical ACtivity After Treatments in Oncology

DEFACTO2
Start date: March 29, 2022
Phase: N/A
Study type: Interventional

Benefits of physical activity (PA) as supportive care in cancer have been widely demonstrated by the scientific community. However, survivors who have completed chemo-radio-immunotherapy treatments doesn't achieve PA recommendations on average. This reinforces the need to identify factors influencing PA level, and to propose a multilevel model (macro-, meso-, micro-level) to understand better what facilitates the adoption and maintenance of active behaviour and what hinders it. To date, there is no ecological model in France explaining this behaviour in the post-treatment phase of breast, colorectal, prostate, and lung cancers. From this initial model, we seek to design an educational and motivational intervention in PA. Thus, the investigators propose to test the feasibility of implementing an individualized program to increase and maintain level of physical activity and to decrease sedentary behaviours in physically inactive cancer survivors. This program is based through and identification of barriers and facilitators of an active lifestyle among this population.

NCT ID: NCT05353387 Not yet recruiting - Breast Cancer Clinical Trials

The Effect of the Motivational Interviewing Technique on Breast and Cervical Cancer Screenings

Start date: April 30, 2022
Phase: N/A
Study type: Interventional

This study will be conducted to evaluate the effect of the motivational interviewing technique applied to menopausal women on their participation in breast and cervical cancer screenings. This is a randomized controlled intervention study in which the study sample will consist of 120 menopausal women, who visit the health care centers in the city of Kutahya. There will be one intervention group with a total of 60 participants and a control group with the same number of participants. The intervention group will have motivational interviews whereas the control group participants will follow the normal protocols.

NCT ID: NCT05353361 Recruiting - Breast Cancer Clinical Trials

A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer

Start date: May 23, 2022
Phase: Phase 2
Study type: Interventional

To evaluate the safety, tolerability and efficacy of SHR-A1811 in combination with pyrotinib or pertuzumab or adebrelimab or albumin-bound paclitaxel in patients with breast cancer.

NCT ID: NCT05352737 Completed - Breast Cancer Clinical Trials

Exploring the Role of Serum Methylmalonic Acid (MMA) in Breast Cancer

Start date: January 22, 2021
Phase:
Study type: Observational

This project aims to investigate the role of MMA in breast cancer. To this end, we will measure MMA on serum samples collected at the time of breast cancer diagnosis, to investigate the role of MMA in predicting long-term recurrence risk, response to neoadjuvant chemotherapy, and its association with age and clinical frailty.

NCT ID: NCT05351424 Recruiting - Prostate Cancer Clinical Trials

AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc

ADELANTE
Start date: May 3, 2022
Phase: N/A
Study type: Interventional

The study aims to develop educational media interventions to prepare Latinx Spanish-speaking radiation oncology patients for a course of breast or prostate cancer radiation therapy and to foster receptivity and informed decision-making around cancer clinical trial participation.

NCT ID: NCT05351021 Completed - Breast Cancer Clinical Trials

Efficacy of Metformin as Preventive Treatment in Paclitaxel Induced Peripheral Neuropathy in Breast Cancer Patients

Start date: April 12, 2022
Phase: Phase 2
Study type: Interventional

At present, there are no FDA-approved treatments for chemotherapy-induced neuropathy. Discrete neuro anti-inflammatory effects of metformin support its repurposing as a neuroprotective agent in patients with neurodegenerative diseases. Therefore, this study aims to evaluate the effect of metformin on the amelioration of paclitaxel induced neuropathy in cancer patients.